CRTX Stock Overview
Focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CRISM Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.06 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.05 |
| Beta | 0.22 |
| 11 Month Change | -47.83% |
| 3 Month Change | n/a |
| 1 Year Change | -83.33% |
| 33 Year Change | -97.74% |
| 5 Year Change | -98.13% |
| Change since IPO | -99.89% |
Recent News & Updates
Shareholder Returns
| CRTX | GB Metals and Mining | GB Market | |
|---|---|---|---|
| 7D | 14.3% | -0.3% | -1.4% |
| 1Y | -83.3% | 5.0% | 6.3% |
Return vs Industry: CRTX underperformed the UK Metals and Mining industry which returned 4.5% over the past year.
Return vs Market: CRTX underperformed the UK Market which returned 6.4% over the past year.
Price Volatility
| CRTX volatility | |
|---|---|
| CRTX Average Weekly Movement | n/a |
| Metals and Mining Industry Average Movement | 7.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CRTX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CRTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 4 | Bob Young | n/a |
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor.
CRISM Therapeutics Corporation Fundamentals Summary
| CRTX fundamental statistics | |
|---|---|
| Market cap | UK£522.33k |
| Earnings (TTM) | -UK£1.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs CRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.39m |
| Earnings | -US$2.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRTX perform over the long term?
See historical performance and comparison